Long-term growth outcomes in children treated for chronic hepatitis C.
Where this comes from
- Record sourced from PubMed, PMID 25241178.
- Also identified by DOI 10.1016/j.jpeds.2014.08.010.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Effects on linear growth were noted in children treated with peginterferon ± ribavirin in the Pediatric Study of Hepatitis C trial. Growth was further examined in a subset of patients followed for up to 6 years post-treatment. No long-term effects on height-for-age z scores were observed that could be attributed to hepatitis C virus treatment.
Medical subject headings
- Antiviral Agents
- Body Height
- Growth
- Hepatitis C, Chronic
- Ribavirin